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Abstract
Background: Staging of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) is mandatory. The
maximum Standard Uptake Value (SUVmax) obtained using F-18 fluorodeoxyglucose positron emission tomography
(FDG-PET) is the best non-invasive technique available for this evaluation, but its performance varies from center to
center. The aim of the present study was to identify FDG-PET predictors of mediastinal malignancy that are able to
minimize intercenter variability and improve the selection of subsequent staging procedures.
Method: A multicenter study of NSCLC patients staged through FDG-PET and endobronchial ultrasonography with
needle aspiration (EBUS-NA) was performed using therapeutic surgery with systematic nodal dissection as gold
standard. Intercenter variability and predictive power for mediastinal malignancy of different FDG-PET measures
were assessed, as well as the role of these measures for selecting additional staging procedures.
Results: One hundred and twenty-one NSCLC patients, of whom 94 (72%) had ≥1 hypermetabolic spots in the
mediastinum, were included in the study. Mean SUVmax of the primary tumor was 12.3 (SD 6.3), and median
SUVmax of the highest hypermetabolic spots in the mediastinum was 3.9 (IQR 2.4-7). Variability of FDG-PET
measures between hospitals was statistically significant (p = 0.016 and p < 0.001 respectively), but lost significance
when SUVmax in the mediastinum was expressed as a ratio or a subtraction from the primary tumor (SUVmax
mediastinum/tumor, p = 0.083; and SUVmax mediastinum - tumor, p = 0.428 respectively). SUVmax mediastinum/
tumor showed higher accuracy in the ROC analysis (AUC 0.77 CI 0.68-0.85, p < 0.001), and showed predictive power
for mediastinal malignancy when using a 0.4 cutoff (OR 6.62, 95%CI 2.98-14.69). Sensitivities and negative predictive
values of clinical staging through EBUS-NA attained values ranging between 57% and 92% after FDG-PET, which
improved with additional techniques when the tumor had a diameter >3 cm and/or a SUVmax mediastinum/tumor
ratio >0.4.
Conclusion: The SUVmax mediastinum/tumor ratio is a good predictor of regional tumor extension in NSCLC. This
measure is not influenced by intercenter variability and has an accuracy of over 70% for the identification of
malignancy when using a 0.4 cutoff.
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Background
An accurate lymph node evaluation is mandatory in pa-
tients with lung cancer (LC) who do not present distant
metastasis at their first examination. The implementa-
tion of F-18 fluorodeoxyglucose positron emission
tomography (FDG-PET) has improved non-invasive LC
staging, because this technique adds metabolic informa-
tion to thoracic imaging and optimizes mediastinal sam-
pling by improving targeting accuracy in comparison
with computed tomography (CT) [1–7].
The maximum Standard Uptake Value (SUVmax)
provides information on the metabolic activity of the
primary tumor and its regional lymph nodes. It is usually
increased in the mediastinum when lymph nodes show
malignant infiltration, although high FDG uptake may
also be observed in inflammatory diseases. Several stud-
ies have assessed the predictive power of SUVmax for
identifying malignant extension of LC to lymph nodes in
the mediastinum, and various cutoffs for mediastinal
malignancy have been proposed, ranging from 2.5 to 5.3
[8–10]. The extensive use of these cutoffs, however, is
limited by the variability in the SUVmax values recorded
at different FDG-PET centers, which is reported to range
between 10% and 15% [11, 12]. The use of ratios be-
tween SUVmax values in the mediastinum and the
tumor has been proposed as a way of homogenizing the
results obtained at different centers and allows the defin-
ition of cutoffs that may not be influenced by intercenter
variability [13–15].
Although the sensitivity and specificity of imaging
techniques for LC staging have improved with the intro-
duction of FDG-PET, the technique lacks sufficient ac-
curacy to guide treatment after the procedure, mainly
because its sensitivity and negative predictive value
(NPV) for malignancy have shown figures below 80% in
most studies [6, 16–18]. Therefore, in accordance with
current guidelines a biopsy is still needed to confirm
lymph node involvement, except in peripheral lung
cancers below 3 cm in diameter and negative results of
imaging studies of the mediastinum in which case the
probability of malignancy is very low [19–21]. Endo-
scopic techniques like endobronchial ultrasonography
with needle aspiration (EBUS-NA) are used to confirm
FDG-PET results. However, the NPV of this technique
after FDG-PET has not been determined, and current
guidelines recommend the performance of invasive tech-
niques such as cervical mediastinoscopy after a negative
EBUS-NA before therapeutic surgery, regardless of the
FDG-PET imaging results.
The aim of the present study was to identify optimal
predictors of mediastinal malignancy from a PET exam
which are able to minimize the variability between
hospitals and improve the selection of subsequent sam-
pling procedures such as EBUS-NA. First, the variability
and predictive power of absolute and relative SUVmax
values obtained from the primary tumor and the medias-
tinum by FDG-PET were assessed in a multicenter LC
study; then, the sensitivity and NPV of EBUS-NA were
calculated according with FDG-PET results.
Methods
Design and patients
A prospective, multicenter study including patients with
a diagnosis of non-small cell lung cancer (NSCLC) was
conducted at five university hospitals between 2010 and
2012. Patients with suspected NSCLC were referred by
their general practitioner to one of the participating
hospitals for diagnosis and staging. Non-invasive staging
examinations included a CT scan of the lung, mediasti-
num and upper abdomen using a multidetector-row
spiral CT scanner, considering nodes in the mediastinum
as abnormal when their short-axis diameter was greater
than 10 mm, and a FDG-PET in patients with no sus-
pected distant metastasis at first examination. Non-
surgical pathological staging was performed by EBUS-NA,
and patients with an EBUS-NA procedure negative for
malignancy in the mediastinum were staged by esophageal
ultrasound with needle aspiration (EUS-NA) and/or cer-
vical mediastinoscopy when their thoracic imaging sug-
gested mediastinal malignancy and/or their primary
tumor was central or over 3 cm in diameter [19, 20]. All
staging procedures were performed 1-3 weeks after the
first hospital visit, to proceed to treatment not later that
one month after that visit, according with fast-track proto-
cols for lung cancer. Patients with hemorrhagic diseases
or coagulation disorders were excluded from staging by
EBUS-NA. Operability was assessed by physical examin-
ation, blood tests and lung function. Only patients with a
diagnosis of NSCLC who were staged by CT, FDG-PET
and EBUS-NA and treated surgically when staging results
were negative were included in the study. Therapeutic sur-
gery with systematic nodal dissection was performed after
EBUS and mediastinoscopy negative for malignancy, and
was considered the gold standard for the present study.
The research protocol was approved by the reference re-
gional ethics committee for the project (Institut de
Recerca en Ciències de la Salut Germans Trias i Pujol,
reference: FIS PS09/01612) and by the local ethics
committees of all participating centers. Written informed
consents were obtained from all participating patients.
F-18 fluorodeoxyglucose positron emission tomography
FDG-PET with a integrated CT equipment (FDG-PET/CT)
(4 hospitals) or performed just after CT (1 hospital) (Phillips,
Amsterdam, The Netherlands; or General Electric, Fairfield,
Connecticut, United States of America), was used to stage
the mediastinum at each hospital in patients with no
suspected distant metastasis at first examination. Prior to
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18 F-FDG administration, patients fasted for at least six
hours and plasma glucose level was confirmed to be inferior
to 175 mg/dL. The patient received intravenously standard
activity 3,7 MBq of 18 F-FDG per kg of weight and rested
60 minute for the scheduled uptake period. FDG-PET im-
ages were acquired from mid-skull to the mid-thigh with
the patient supine, reconstructed with a standard iterative
algorithm, and reformatted into axial, coronal, and sagital
views. Administered activity, time of administration, and
patient's body weight were recorded for calculation of max-
imum standardized uptake values (SUV max). Recovered
images were interpreted by a nuclear medicine physician
who evaluated both the appearance of the primary lung
tumor and the hypermetabolic lymph nodes in the mediasti-
num. Standard uptake values of examined regions were
assigned by the software of the equipment used in each hos-
pital. To quantify the maximal metabolic activity of lymph
nodes in the mediastinum their highest SUVmax was mea-
sured, as an absolute value, as a ratio between this value and
the SUVmax of the primary tumor, and after the subtraction
of this second value from this highest SUVmax in the medi-
astinum [13–15]. Homogeneity of FDG-PET between
hospitals was assessed through comparisons of the SUVmax
values of primary lung tumors and of lymph node regions
with the highest SUVmax in the mediastinum, both as abso-
lute and as relative values.
Cytopathologic staging
EBUS-NA was performed in an outpatient setting using
a flexible bronchoscope with a linear scanning trans-
ducer (BFUC180F, Olympus Optical Co Ltd., Tokyo,
Japan). The bronchoscope has a convex distal probe cap-
able of producing linear parallel scans of the mediastinal
and peribronchial tissues and a working channel suitable
for the performance of NA under direct ultrasound
guidance. Local anesthesia and sedation were achieved
using topical lidocaine spray and intravenous midazolam,
propofol and/or fentanyl in accordance with standard rec-
ommendations [22]. Regional lymph node stations of the
mediastinum and hilar regions (stations 2, 4, 7, 10 and 11)
were systematically imaged and measured, and all nodes
with a short-axis diameter of 5 mm or more were sampled
with a 22-gauge needle (NA-201SX-4022, Olympus
Optical Co Ltd.).
Samples were categorized according to whether they
had been extracted from a normal node, showing lym-
phocytes and no neoplastic cells, or from a metastatic
node, with groups of neoplastic cells. Aspirates contain-
ing only bronchial or blood cells, non-diagnostic atypical
cells or insufficient material were considered inadequate.
Every identified node was sampled at least three times,
unless rapid on-site evaluation performed by a patholo-
gist during the procedure confirmed the adequacy of the
sample after the first or the second aspiration [23, 24].
Patients with negative EBUS-NA results were staged
through EUS-NA, in left-sided tumors with abnormal lymph
nodes by CT and/or FDG-PET in mediastinal regions 7, 8
or 9 [25–28]. Samples obtained through this procedure were
categorized with the same criteria used for EBUS-NA. Pa-
tients with negative results in all the endoscopic procedures
underwent cervical mediastinoscopy in accordance with
guidelines [19, 20]. Systematic nodal dissection was per-
formed during therapeutic surgery as the gold standard pro-
cedure for mediastinal staging.
Statistical analysis
Statistical analyses were performed using the SPSS stat-
istical software package version 18 (SPSS Inc., Chicago,
IL, USA). Results obtained from categorical variables are
expressed as absolute and relative frequencies, and
results for continuous variables as means and standard
deviations (SD) when the distribution was normal, or as
medians and interquartile ranges (IQRs) when the distri-
bution was not normal.
First, absolute SUVmax values for the primary tumor and
the mediastinal node with highest FDG-PET uptake were
measured, and the variability between hospitals assessed
using one way ANOVA. Relative values of SUVmax in
mediastinum (using SUVmax of the primary tumor as the
reference) were calculated, both as a ratio (SUVmax medias-
tinum/SUVmax tumor) and as a subtraction (SUVmax
mediastinum - SUVmax tumor), and the intercenter vari-
ability of these values was measured (one way ANOVA).
Second, the predictive power of absolute and relative
SUVmax values for mediastinal malignancy was
assessed, using pathology results as gold standard and
applying logistic regression. The accuracies of different
measures of SUVmax in the mediastinum were exam-
ined using ROC analyses and area under the curve
(AUC). SUVmax cutoffs with maximal accuracy for the
identification of mediastinal malignancy were defined,
and their predictive powers for the identification of ma-
lignancy were calculated through univariate and multi-
variate logistic regression analyses. The results obtained
in these analyses were expressed as crude and adjusted
odds ratios (OR), with 95% confidence intervals (CI). All
variables showing an association with the outcome vari-
able (p < 0.10) in the univariate analysis were included in
the multivariate models.
Finally, to determine the need for additional staging
techniques after negative results in EBUS-NA, the
sensitivity and NPV of this endoscopic technique for the
diagnosis of mediastinal malignancy were assessed in pa-
tients at high and low risk according to their SUVmax
values. Results were compared using the chi-square test.
All tests used in the analyses were two-sided, and a
p value of 0.05 or less was reported as statistically
significant.
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Results
One hundred and twenty-one patients from five hospi-
tals with a diagnosis of NSCLC were enrolled in the
study over two years. Their median age was 65.7 years;
adenocarcinoma was the most frequent tumor (52.9%),
and a FDG-PET showed one or more hypermetabolic
lymph nodes in the mediastinum in 77.7% of patients.
The mean SUVmax of the primary tumor was 12.3 (SD
6.3) and the median SUVmax of the mediastinal node
with the highest FDG-PET uptake was 3.9 (IQR 2.4-7.0).
Mediastinal malignancy was diagnosed in 65 patients
(53.7%), with EBUS-NA being the procedure which
attained this diagnosis most frequently. Mediastinal
lymph node involvement was confirmed through sys-
tematic nodal dissection performed during therapeutic
surgery in six patients with negative endoscopic proce-
dures and cervical mediastinoscopies (Table 1).
Between-center FDG-PET variability in absolute SUV-
max obtained from the tumor and the hypermetabolic
image with the highest FDG uptake in the mediastinum
was statistically significant (p = 0.016 and p < 0.001 re-
spectively; one way ANOVA) (Figs. 1a and 1b). This vari-
ability in the mediastinum values disappeared when the
SUVmax of the image with highest FDG uptake was ad-
justed for the SUVmax of the tumor, either as a ratio
(SUVmax mediastinum/tumor) or as a subtraction (SUV-
max mediastinum – tumor) (p = 0.083 and p = 0.428 re-
spectively; one way ANOVA) (Figs. 2a and 2b).
SUVmax of the primary tumor did not show predictive
power for identifying mediastinal extension of the dis-
ease (OR 0.98, 95%CI 0.92-1.04), but SUVmax in the
mediastinum was clearly associated with malignancy
when attaining values above the median (3.9). Equivalent
results were found for the median values of the ratio be-
tween SUVmax in the mediastinum and SUVmax of the
tumor (0.4) and the subtraction of this latter value from
the SUVmax in the mediastinum (-6.1) (Table 2). Areas
under the curve at ROC analysis for SUVmax in the
mediastinum (AUC 0.77 CI 0.69-0.86, p < 0.001) (Fig. 3a)
and for the ratio between this value and the SUVmax of
the tumor (AUC 0.77 CI 0.68-0.85, p < 0.001) (Fig. 3b)
were equivalent, confirming that the two measures were
equally useful. The result of subtracting the SUVmax of
the tumor from the highest SUVmax in the mediastinum
showed a lower figure, still statistically significant (AUC
0.74 CI 0.6-0.83, p < 0.001). Cutoffs of 4 for SUVmax in
the mediastinum and of 0.4 for the ratio between the
SUVmax in the mediastinum and the tumor showed
similar sensitivities, specificities and accuracies over 70%
for the identification of mediastinal malignancy (Table 3).
Accordingly, these two measures of SUVmax in the
mediastinum may be considered equivalent, with the ad-
vantage of a greater homogeneity between centers when
using the SUVmax mediastinum/tumor ratio.
Younger age and adenocarcinoma type were predictors
of mediastinal involvement in NSCLC. The observation
of a single hypermetabolic image in the mediastinum
during FDG-PET did not reach statistical significance as
a predictor of mediastinal malignancy (OR 2.34, 95% CI
0.89-6.22), but multiple FDG-PET hypermetabolic lymph
nodes were significantly associated with the spread of
NSCLC to the mediastinum (OR 3.87, 95% CI 1.40-
10.66). SUVmax in the mediastinum above 4 and SUV-
max mediastinum/tumor ratio above 0.4 showed similar
predictive power for mediastinal malignancy (OR 10.68,
95% CI 4.55-25.10 and OR 6.62, 95% CI 2.98-14.69 re-
spectively) (Table 4), which did not change significantly
after adjusting for age, uni- and multilevel positive FDG-
PET in the mediastinum and type of tumor in the multi-
variate analysis (OR 10.81, 95% CI 4.32-27.07 and OR
5.75, 95% CI 2.49-13.29 respectively).
EBUS-NA confirms an extension of NSCLC to the
mediastinum in more that 15% of the cases
Table 1 Patient characteristics (n = 121)
Sociodemographic data
Age (years), mean (SD) 65.7 (9.2)
Gender (female), n (%) 17 (14.0)
Tumor characteristics
Pathology, n (%)
Squamous-cell carcinoma 46 (38.0)
Adenocarcinoma 64 (52.9)




Tumor size, n (%):
≤ 3 cm 46 (38.0)
> 3 cm and ≤7 cm 57 (47.1)
> 7 cm 18 (14.9)
F-18 fluorodeoxyglucose Positron
emission tomography (FDG-PET)
SUVmax tumor, mean (SD) 12.3 (6.3)
Single hypermetabolic image in
the mediastinum, n (%)
50 (41.3)
Multiple hypermetabolic images
in the mediastinum, n (%)
44 (36.4)
SUVmax mediastinum, median (IQR) 3.9 (2.4-7.0)
Staging of the mediastinum
Malignancy extended to mediastinal
lymph nodes
65 (53.8)
Technique diagnosing mediastinal malignancy
EBUS-NA 53 (43.8)
EUS-NA or mediastinoscopy 6 (5.0)
Surgical lymphadenectomy 6 (5.0)
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independently of FDG-PET results in our study. Sensi-
tivities and negative predictive values of EBUS-NA for
the diagnosis of mediastinal malignancy, however, did
not attain values above 90% for most of the subgroups
categorized according to SUVmax in the mediastinum,
with equivalent figures for SUVmax in the mediastinum
and SUVmax mediastinum/tumor ratios (p > 0.05, chi
square test) (Table 5). This finding supports the use of
additional staging techniques such as EUS-NA and/or
cervical mediastinoscopy to achieve accurate medias-
tinal staging previous to therapeutic surgery. In tu-
mors with a SUVmax below the cutoff and diameters
of 3 cm or less, however, the use of additional
techniques in clinical staging in our study did not in-
crease the presurgical sensitivity and negative predict-
ive value, with equivalent results when there is none
Fig. 1 a Variability of FDG-PET between hospitals (absolute values): Maximum Standard Uptake Value (SUVmax) of the tumor (p =0.016, one way
ANOVA). b Variability of FDG-PET between hospitals (absolute values): Highest maximum Standard Uptake Value (SUVmax) in the mediastinum
(p < 0.001, one way ANOVA)
A B
Fig. 2 a Variability of FDG-PET between hospitals (relative values): Ratio highest maximum Standard Uptake Value (SUVmax) in the mediastinum/
SUVmax tumor (p = 0.083; one way ANOVA). b Variability of FDG-PET between hospitals (relative values): Highest maximum Standard Uptake Value
(SUVmax) in the mediastinum minus SUVmax tumor (p = 0.428; one way ANOVA)
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or one single hypermetabolic lymph node in the
mediastinum, or multiple FDG-PET hot spots (p >
0.05, chi square test). These results suggest that in
this clinical situation it may be possible to proceed to
therapeutic surgery and systematic nodal dissection
after a negative EBUS-NA exam.
Discussion
A highest SUVmax value in the mediastinum of over 4
proved to be a good predictor of mediastinal dissemin-
ation in patients with LC in our study. However, this
FDG-PET measure showed variability between centers, a
finding that limits its use a marker in staging for a spe-
cific hospital. This variability was corrected when the
highest SUVmax value in the mediastinum was adjusted
by the SUVmax of the primary tumor, either as a ratio
(SUVmax mediastinum/tumor) or as a subtraction
(SUVmax tumor - mediastinum). The ratio between the
SUVmax in the mediastinum and the primary tumor
emerged as the best relative predictor of nodal involve-
ment by LC when attaining values over 0.4, showing a
similar accuracy to SUVmax in the mediastinum
expressed as an absolute value, without its intercenter
variability.
The presence of significant intercenter differences in
SUVmax values obtained from FDG-PET in LC patients
is confirmed in our study, that shows that these differ-
ences can be corrected if the SUVmax of the primary
tumor is used to adjust mediastinal values. Intercenter
variability in SUVmax in the tumor and mediastinum
has been reported in previous studies, depending on the
scanner, reconstruction protocols [11, 12], and time
Table 2 SUVmax values as a predictor of mediastinal malignancy
Quartile categories OR (95% IC) p
SUVmax tumor 11.4 (SD 5.3) 0.98 (0.92-1.04) 0.469






































Fig. 3 a Prediction of metastasis in the mediastinum in lung cancer by FDG-PET: Area under the curve (AUC) at ROC analysis for the maximum Standard
Uptake Value (SUVmax) in mediastinum. Area under de curve (AUC 0.77 CI 0.69-0.86, p< 0.001). b Prediction of metastasis in the mediastinum in lung cancer
by FDG-PET: Area under the curve (AUC) at ROC analysis for the maximum Standard Uptake Value (SUVmax) in mediastinum divided by the SUVmax of
tumor (AUC 0.77 CI 0.68-0.85, p< 0.001)
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between dose injection and imaging [14]. The use of the
ratio between the SUVmax in the mediastinum and
tumor (SUVmax mediastinum/tumor) was first pro-
posed by Cerfolio and cols. as a way of correcting
intercenter variability [13], and this relative value has
been used successfully by other authors to identify
mediastinal malignancy [14, 15]. Our study confirms
the utility of the adjustment of SUVmax in the medi-
astinum using the SUVmax of the tumor, either as a
ratio or as a subtraction, in order to avoid intercenter
variability, allowing the comparison of results between
centers.
The SUVmax mediastinum/tumor ratio emerged as
the best predictor of mediastinal involvement in LC.
This measure was not affected by intercenter variabil-
ity, and attained a high AUC value, equivalent to the
figure obtained by SUVmax when expressed as an ab-
solute value and higher than the subtraction SUVmax
mediastinum - tumor. The SUVmax mediastinum/
tumor ratio showed an OR 6.62 (2.98-14.69) for me-
diastinal malignancy when above 0.4, similar to the
OR of 10.68 (4.55-25.10) found for absolute values of
SUVmax in the mediastinum when above 4. This
SUVmax mediastinum/tumor ratio cutoff attained a
sensitivity of 70.8 and an accuracy of 71.9% for the
identification of malignancy, similar to the results
achieved using absolute values. The cutoffs proposed
in previous studies for SUVmax mediastinum/tumor
ratios for attaining a sensitivity above 70% have
ranged between 0.28 and 0.56 [13–15], and our re-
sults confirm that the use of a 0.4 cutoff, inside this
range, attains a sensitivity above this figure. To attain
an equivalent sensitivity for the identification of ma-
lignancy, absolute SUVmax values in the mediastinum
ranging between 2.5 and 5.3 have been proposed [8–
10, 17], but they remain unsuitable for intercenter
comparisons.
Adenocarcinoma type, younger age and multiple FDG-
PET hypermetabolic lymph nodes, were significantly as-
sociated with extension to the mediastinum of NSCLC
in the present study, but the predictive power of the
SUVmax mediastinum/tumor ratio for malignant exten-
sion did not change after adjustment for these variables.
However, in spite of its usefulness for the identification
of mediastinal extension in LC, FDG-PET did not obtain
an accuracy above 80%, and sampling of the lymph
nodes in the mediastinum is required for the
confirmation of positive imaging results and the identifi-
cation of malignancy in patients who have negative
FDG-PET exams but are at a high risk of regional exten-
sion [4, 5, 7, 17]. EBUS-NA is the first approach for me-
diastinal sampling after FDG-PET, and in the present
study it increased the accuracy of clinical staging inde-
pendently of the FDG-PET results. EBUS-NA only
attained a sensitivity over 80% when FDG-PET value was
above the cutoff, however, and showed a NPV below
70% in this subgroup of patients. These results are not
high enough to obviate the need for additional staging
procedures before surgery such as EUS-NA and medias-
tinoscopy in order to minimize understaging, except in
patients with tumors with a diameter of 3 cm or below,
where the NPV of clinical staging with EBUS-NA did
not increase with additional sampling through EUS and/
or mediastinoscopy. These findings support the recom-
mendation in current guidelines of mediastinal sampling
using EBUS-NA after FDG-PET in NSCLC [19, 20], and
suggest that this endoscopic technique may be enough
for presurgical staging in patients with lung tumors up
to 3 cm in diameter, when the highest SUVmax medias-
tinum/tumor ratio was below 0.4.
Conclusion
SUVmax mediastinum and the SUVmax mediasti-
num/tumor ratio are both good predictors of medias-
tinal malignancy in NSCLC, and both show
accuracies over 70% at values above 4 and 0.4 re-
spectively. When SUVmax is measured as a ratio it is
not influenced by intercenter variability, and allows
comparisons between hospitals without additional ad-
justments. The presence of multiple FDG-PET hyper-
metabolic lymph nodes in the mediastinum predicts
the regional extension of the tumor, but presents a
much lower OR than SUVmax, and thus has a lower
diagnostic power than the measurement of SUV.
However, most FDG-PET results obtained in the
mediastinum during LC staging would need to be
Table 3 Accuracy of cut-off SUVmax values for mediastinal
malignancy, expressed as absolute value or as a ratio
Sensitivity Specificity PPV NPV Accuracy
SUVmax mediastinum >4 72.3 80.4 81.0 71.4 76.0
SUVmax Mediastinum
SUVmax Tumor > 0:4 70.8 73.2 75.4 68.3 71.9
Table 4 Univariate analysis of predictors for mediastinal malignancy
OR (CI) p
Age 0.95 (0.92-0.99) .029
Gender (women) 2.31 (0.76-7.02) .140
Tumor size 0.81 (0.48-1.37) .435
Adenocarcinoma 2.45 (1.18-5.10) .017
Single hypermetabolic node 2.34 (0.89-6.22) .086
Multiple hypermetabolic nodes 3.87 (1.40-10.66) .009
SUVmax Mediastinum > 4 10.68 (4.55-25.10) <.001
SUVmax Mediastinum
SUVmax Tumor > 0:4 6.62 (2.98-14.69) <.001
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confirmed through semi-invasive techniques, given
that the predictive values of the technique remain
below 90%. EBUS-NA increases the accuracy of FDG-
PET, and may be enough for presurgical staging in
small tumors with low SUVmax mediastinum/tumor
values.
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